Trial Profile
A Phase 2b, Multicenter, Randomized, Double-Blind, Parallel, Placebo-Controlled Study to Evaluate the Efficacy and Safety of SUN11031 for Injection Administered Subcutaneously Twice Daily for 12 Weeks to Subjects Having Cachexia Associated With Chronic Obstructive Pulmonary Disease
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 20 Feb 2024
Price :
$35
*
At a glance
- Drugs Ghrelin (Primary)
- Indications Cachexia
- Focus Therapeutic Use
- Sponsors Asubio Pharmaceuticals; Daiichi Sankyo Company
- 22 Dec 2014 New trial record